Participant flow

A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency · Source last updated 2025-07-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Oral rucaparib (monotherapy). Rucaparib: Rucaparib will be administered daily.

   id

   FG000

   title

   Rucaparib

2. description

   Oral abiraterone acetate (monotherapy, given in combination with prednisone). Oral enzalutamide (monotherapy). Intravenous docetaxel (monotherapy, given in combination with prednisone or prednisolone). Abiraterone acetate or Enzalutamide or Docetaxel: Abiraterone acetate and enzalutamide will be administered daily. Docetaxel will be administered every 3 weeks.

   id

   FG001

   title

   Abiraterone Acetate or Enzalutamide or Docetaxel

3. description

   Oral rucaparib (monotherapy). Rucaparib: Rucaparib will be administered daily. Participants from the Abiraterone Acetate/Enzalutamide/Docetaxel arm who completed the Treatment Phase and radiographically progressed by independent radiology review (IRR) may receive rucaparib treatment during the Cross-Over Phase. After analysis of the primary endpoint, investigator-assessed radiographic disease progression will be used for cross-over eligibility evaluation.

   id

   FG002

   title

   Rucaparib (Cross-Over Phase)

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         5

      3. group Id

         FG002

         num Subjects

         0

      type

      Never initiated study drug

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         270

      2. group Id

         FG001

         num Subjects

         135

      3. group Id

         FG002

         num Subjects

         0

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         270

      2. group Id

         FG001

         num Subjects

         130

      3. group Id

         FG002

         num Subjects

         0

      type

      Received at Least 1 Dose of Study Drug

   3. achievements

      1. group Id

         FG000

         num Subjects

         270

      2. group Id

         FG001

         num Subjects

         130

      3. group Id

         FG002

         num Subjects

         0

      type

      Safety Population

   4. achievements

      1. group Id

         FG000

         num Subjects

         270

      2. group Id

         FG001

         num Subjects

         130

      3. group Id

         FG002

         num Subjects

         0

      comment

      Treatment period completion was defined as discontinuation when criteria for treatment discontinuation were met.

      type

      COMPLETED

   5. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         5

      3. group Id

         FG002

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Treatment Phase

2. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         70

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         70

      type

      Received at Least 1 Dose of Study Drug

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         70

      type

      Safety Population

   4. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         70

      comment

      Crossover period completion was defined as discontinuation when criteria for treatment discontinuation were met, or study closure.

      type

      COMPLETED

   5. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Cross-Over Phase

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice